Han Chuyi, Xiao Sutong, Xing Zhenyu, Xu Xiaohui, Wang Mao, Han Xianglong, Adeli Mohsen, Qiu Li, Ye Ling, Cheng Chong
Department of Endodontics, Department of Orthodontics, State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, 610041, China.
Department of Medical Ultrasound, West China Hospital, Sichuan University, Chengdu, 610041, China.
Adv Mater. 2025 Jan;37(3):e2407644. doi: 10.1002/adma.202407644. Epub 2024 Oct 14.
Clinical immune checkpoint blockade (ICB)-based immunotherapy of malignant tumors only elicits durable responses in a minority of patients, primarily due to the highly immunosuppressive tumor microenvironment. Although inducing immunogenic cell death (ICD) through reactive oxygen biocatalyst represents an attractive therapeutic strategy to amplify ICB, currently reported biocatalysts encounter insurmountable challenges in achieving high ROS-generating activity to induce potent ICD. Here, inspired by the natural catalytic characteristics of NADPH oxidases, the design of efficient, robust, and electron-rich Pt-based redox centers on the non-stoichiometric WO substrates (Pt─WO) to serve as bioinspired reactive oxygen biocatalysts to potently activate the ICD, which eventually enhance cancer immune responses and amplifies the ICB-based immunotherapy is reported. These studies demonstrate that the Pt─WO exhibits rapid electron transfer capability and can promote the formation of electron-rich and low oxophilic Pt redox centers for superior reactive oxygen biocatalysis, which enables the Pt─WO-based inducers to trigger endoplasmic reticulum stress directly and stimulate immune responses potently for amplifying the anti-PD-L1-based ICB therapy. This bioinspired design provides a straightforward strategy to engineer efficient, robust, and electron-rich reactive oxygen biocatalysts and also opens up a new avenue to create efficient ICD inducers for primary/metastatic tumor treatments.
基于临床免疫检查点阻断(ICB)的恶性肿瘤免疫疗法仅在少数患者中引发持久反应,主要原因是肿瘤微环境具有高度免疫抑制性。尽管通过活性氧生物催化剂诱导免疫原性细胞死亡(ICD)是一种有吸引力的增强ICB的治疗策略,但目前报道的生物催化剂在实现高活性氧生成活性以诱导强效ICD方面面临无法克服的挑战。在此,受烟酰胺腺嘌呤二核苷酸磷酸氧化酶的天然催化特性启发,设计了一种在非化学计量的WO基底上高效、稳健且富电子的铂基氧化还原中心(Pt─WO),作为受生物启发的活性氧生物催化剂,以有效激活ICD,最终增强癌症免疫反应并放大基于ICB的免疫疗法。这些研究表明,Pt─WO具有快速的电子转移能力,能够促进富电子且低亲氧性的铂氧化还原中心的形成,以实现卓越的活性氧生物催化,这使得基于Pt─WO的诱导剂能够直接触发内质网应激并有效刺激免疫反应,从而放大基于抗程序性死亡受体配体1(PD-L1)的ICB治疗。这种受生物启发的设计提供了一种直接的策略来设计高效、稳健且富电子的活性氧生物催化剂,也为开发用于原发性/转移性肿瘤治疗的高效ICD诱导剂开辟了一条新途径。